Medcube Limited

	Page
Company Information	1
Balance Sheet	2—3
Notes to the Financial Statements	4—5

Page 1

Page 2

Medcube Limited

Balance Sheet

As At 31 December 2024

Balance Sheet

Registered number: 08888419

		2024		2023
	Notes	€	€	€	€
FIXED ASSETS
Investments	4		20,000		20,000

			20,000		20,000
CURRENT ASSETS
Debtors	5	8,278,000		7,568,000
Cash at bank and in hand		25,439		3,261

		8,303,439		7,571,261
Creditors: Amounts Falling Due Within One Year	6	(2,621,540 )		(1,523 )

NET CURRENT ASSETS (LIABILITIES)			5,681,899		7,569,738

TOTAL ASSETS LESS CURRENT LIABILITIES			5,701,899		7,589,738

Creditors: Amounts Falling Due After More Than One Year	7		-		(1,500,932 )

NET ASSETS			5,701,899		6,088,806

CAPITAL AND RESERVES
Called up share capital	8		1,159,056		1,159,056
Share premium account			6,558,011		6,558,011
Capital redemption reserve			(23,451 )		(23,451 )
Profit and Loss Account			(1,991,717 )		(1,604,810 )

SHAREHOLDERS' FUNDS			5,701,899		6,088,806

Page 2

Page 3

Medcube Limited

Balance Sheet (continued)

As At 31 December 2024

For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Franck Legoux Director	Mr Thomas Joly Director
29 September 2025

The notes on pages 4 to 5 form part of these financial statements.

Page 3

Page 4

Medcube Limited

Notes to the Financial Statements

For The Year Ended 31 December 2024

Notes to the Financial Statements

1. General Information

Medcube Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08888419 . The registered office is The Scalpel, 18th Floor, 52 Lime Street, London, United Kingdom, EC3M 7AF.

These financial statements were authorised for issue by the Board on 29/09/2025.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities — "The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland" and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

The functional and presentational currency of the financial statements is Euros (€).

2.2. Going Concern Disclosure

The accounts have been prepared on a going concern basis.

The directors, having made such enquiries as they considered appropriate and having a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, have prepared the financial statements on a going concern basis. The financial statements do not include any adjustments that would result from withdrawal of this support

2.3. Financial Instruments

The company recognises financial assets and liabilities when it becomes a party to the contractual provisions of the instrument.

Financial assets comprise trade and other debtors, including loan notes and bonds. These are initially measured at the transaction price and subsequently at historical cost less impairment. Financial liabilities comprise trade and other creditors and borrowings, which are measured at amortised cost.

The company does not hold or issue derivatives.

2.4. Foreign Currencies

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

2.5. Taxation

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

2.6. Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

2.7. Share Capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of cash or other resources received or receivable, net of direct costs of issuing equity instruments. If payment is deferred and time value of money is material, initial measurement is on a present value basis.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 6 (2023: 6)

Page 4

Page 5

Medcube Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2024

4. Investments

	Unlisted
	€
Cost or Valuation
As at 1 January 2024	20,000

As at 31 December 2024	20,000

Provision
As at 1 January 2024	-

As at 31 December 2024	-

Net Book Value
As at 31 December 2024	20,000

As at 1 January 2024	20,000

5. Debtors

	2024	2023
	€	€
Due after more than one year
Other debtors	8,278,000	7,568,000

Other debtors include €8,278,000 (2023: €7,568,000) in respect of convertible bonds. These bonds are non-interest bearing, carried at historical cost less impairment, and are repayable after more than one year.

6. Creditors: Amounts Falling Due Within One Year

	2024	2023
	€	€
Other loans	2,610,593	-
Accruals	10,947	1,523

	2,621,540	1,523

Other loans include €2,610,593 of loan notes with the interest charged at 17.5% p.a. The loan notes were converted into equity within 12 months of the reporting period end

7. Creditors: Amounts Falling Due After More Than One Year

	2024	2023
	€	€
Other loan	-	1,500,932

8. Share Capital

	2024	2023
Allotted, called up and fully paid	€	€
406,762 Ordinary Shares of € 1.00 each	406,762	406,762
744,557 Ordinary B shares of € 1.00 each	744,557	744,557
7,737 Ordinary C shares of € 1.00 each	7,737	7,737

	1,159,056	1,159,056

Page 5

Directors	Mr Geoffroy Berbesson
	Mr Thierry Degroote
	Dealbydeal Invest
	Mr Bertrand Pivin
	Mr Franck Legoux
	Mr Thomas Joly

Company Number	08888419

Registered Office	The Scalpel, 18th Floor
	52 Lime Street
	London
	United Kingdom
	EC3M 7AF